FARMINGDALE, N.Y.--(BUSINESS WIRE)--July 17, 2006--Enzo Biochem, Inc. (NYSE:ENZ - News) announced today that it has received regulatory approval from the Helsinki Committee of Hebrew University-Hadassah Medical Center in Jerusalem, Israel to initiate a Phase II randomized double-blind clinical trial of EGS21 for the treatment of non-alcoholic steatohepatitis (NASH) or fatty liver disease.
